Add BrightSurf on Google Email

Science News for June 4, 2023


Association of immunotherapy duration with overall survival in advanced non–small cell lung cancer – this study is being released to coincide with a poster presentation at the 2023 ASCO annual meeting

A study published in JAMA Oncology suggests that stopping immunotherapy after two years for patients with advanced non–small cell lung cancer who remain responsive may be a reasonable strategy, providing sustained clinical benefit. The findings provide reassurance for patients and their healthcare providers.

SourceJAMA Network·JournalJAMA Oncology·DateJun 4, 2023

Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer

A retrospective cohort study suggests that stopping immunotherapy treatment at two years is a valid strategy without compromising overall survival. The researchers analyzed data from 1,091 patients and found similar overall survival probabilities between those who stopped treatment and continued it indefinitely.

SourceUniversity of Pennsylvania School of Medicine·JournalJAMA Oncology·DateJun 4, 2023
Kestrel 3000 Pocket Weather Meter

Kestrel 3000 Pocket Weather Meter measures wind, temperature, and humidity in real time for site assessments, aviation checks, and safety briefings.

Researchers from Tel Aviv University and UCLA developed a method of deep-brain stimulation during sleep to improve memory consolidation

Researchers from Tel Aviv University and UCLA developed a method to improve memory consolidation by inducing deep-brain stimulation during sleep. The study found that precise timing of electrical stimulation enhances synchronization between the hippocampus and frontal cortex, leading to improved accuracy in recalling memories.

SourceTel-Aviv University·JournalNature Neuroscience·DateJun 4, 2023

Research reveals ants inflict pain with neurotoxins

University of Queensland researchers have identified ant venoms that target nerve cells, leading to a long-lasting pain signal. The discovery provides new insights into the mechanisms of pain and may lead to the development of new pain treatments.

SourceUniversity of Queensland·JournalNature Communications·TypeExperimental study·DateJun 4, 2023

New model enhances wave forecasting in ice-covered waters

A new parameterization scheme incorporating sea ice thickness improves wave forecasting accuracy in the Marginal Ice Zone. The model effectively captures directional attenuation and spreading of waves caused by sea ice.

SourceInstitute of Atmospheric Physics, Chinese Academy of Sciences·JournalAdvances in Atmospheric Sciences·DateJun 4, 2023

New drug delays progression of glioma, a deadly brain cancer

A new targeted therapy drug vorasidenib has been shown to extend treatment time without worsening glioma in people with IDH1 and IDH2 mutations. The study suggests a possible new treatment option for slow-growing but deadly brain tumors, delaying chemotherapy and radiation.

SourceUniversity of California - Los Angeles Health Sciences·JournalNew England Journal of Medicine·DateJun 4, 2023
Sky-Watcher EQ6-R Pro Equatorial Mount

Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.

Clinical trial points to treatment advances for glioma patients for first time in decades

A phase 3 clinical trial by Dana-Farber Cancer Institute has shown vorasidenib significantly prolongs progression-free survival and delays radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma. Treatment with vorasidenib can delay cognitive dysfunction in patients and preserve their quality of life.

SourceDana-Farber Cancer Institute·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJun 4, 2023

Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

The Phase 3 S1826 trial demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma treated with nivolumab and chemotherapy. The therapy was well-tolerated, with few serious immune-related side effects.

SourceSWOG Cancer Research Network·TypeRandomized controlled/clinical trial·DateJun 4, 2023

Whales not to be counted on as ‘climate savers’: study

A recent study led by Griffith University found that whales do not significantly contribute to the removal of atmospheric carbon, contrary to previous hopes. The research suggests that other methods, such as protecting marine environments and natural carbon capture, are more effective in reducing greenhouse gases.

SourceGriffith University·JournalFrontiers in Marine Science·TypeComputational simulation/modeling·DateJun 4, 2023
SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

Robot ‘chef’ learns to recreate recipes from watching food videos

Researchers trained a robotic chef to watch and learn from cooking videos, enabling it to identify ingredients and actions. The robot recognized 93% of the correct recipe from 16 videos, including variations and new recipes, showcasing its potential for automated food production and cost-effective deployment.

SourceUniversity of Cambridge·JournalIEEE Access·DateJun 4, 2023

Saving moths may be just as important as saving the bees

A new study suggests that moths are visiting just as many plants as bees and play a crucial role in supporting urban plant communities. However, their more complex life cycle and specific plant requirements make them less resilient to urbanization pressure.

SourceUniversity of Sheffield·JournalEcology Letters·TypeExperimental study·DateJun 4, 2023